Evidence map›Paper›PMID 33656274›Full record

ArticleCurrent protocols2021

Generation and Use of Recombinant Galectins.

Shang-Chuen Wu, Anu Paul, Alex Ho, Kashyap R Patel, Jerry William Lynn Allen, Hans Verkerke, Connie M Arthur, Sean R Stowell

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Current protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Analysis of Galectin Binding to Blood Group Expressing Bacteria.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shang-Chuen WuJoint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Anu PaulJoint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Alex HoJoint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Kashyap R PatelJoint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Jerry William Lynn AllenJoint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Hans VerkerkeCenter for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia.
Connie M ArthurCenter for Transfusion Medicine and Cellular Therapies, Emory University School of Medicine, Atlanta, Georgia.
Sean R StowellJoint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Brigham and Women's Hospital · USEmory University · USHarvard University · US

Funding

Examination of Innate Immunity Against Molecular MimicryDP5OD019892 · OD · EMORY UNIVERSITY · PI STOWELL, SEAN R · 2014 to 2018
$2.2M
Integrating microbial glycan arrays with genomic sequences to study host microbe interactionsU01CA242109 · NCI · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D, STOWELL, SEAN R · 2019 to 2021
$1.5M
NCI NIH HHS U01 CA242109NIH HHS DP5 OD019892NIH HHS U01 CA242109
6 · The paper itself

Abstract

Galectins are soluble carbohydrate binding proteins that can bind β-galactose-containing glycoconjugates by means of a conserved carbohydrate recognition domain (CRD). In mammalian systems, galectins have been shown to mediate very important roles in innate and adaptive immunity as well as facilitating host-pathogen relationships. Many of these studies have relied on purified recombinant galectins to uncover key features of galectin biology. A major limitation to this approach is that certain recombinant galectins purified using standard protocols are easily susceptible to loss of glycan-binding activity. As a result, biochemical studies that employ recombinant galectins can be misleading if the overall activity of a galectin remains unknown in a given assay condition. This article examines fundamental considerations when purifying galectins by lactosyl-sepharose and nickel-NTA affinity chromatography using human galectin-4N and -7 as examples, respectively. As other approaches are also commonly applied to galectin purification, we also discuss alternative strategies to galectin purification, using human galectin-1 and -9 as examples. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Purification of galectins using lactosyl-sepharose affinity chromatography Basic Protocol 2: Purification of human galectin-7 using a nickel-NTA affinity chromatography column Alternate Protocol 1: Iodoacetamide alkylation of free sulfhydryls on galectin-1 Alternate Protocol 2: Purification of human galectin-9 using lactosyl-sepharose column chromatography.

Indexed as

CarbohydratesGalectinsAlkylationAnimalsChromatography, AffinityGalactoseHumansCarbohydratesGalactoseGalectinsgalectingalectin-1 alkylation using iodoacetamidegalectin-4galectin-7galectin-9 purification using Tris buffergalectin stabilitylactosyl-sepharose chromatographystable and active galectin-9

Identifiers

PMID33656274
OpenAlexW3134526197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.